Skip left side navigation and go to content

NIH State of the Science Symposium on Myelodysplastic Syndromes (MDS)


Wednesday, September 7, 2011

7:00 - 5:00 p.m. Registration

8:00 a.m. Introductions and Opening Remarks

  Susan B. Shurin, M.D.
Acting Director, NHLBI

Hal E. Broxmeyer, Ph.D.
Indiana University School of Medicine

8:20 a.m. Plenary Talk

MDS: What Have We Achieved in the Last Ten Years?
Pierre Fenaux, M.D., Ph.D.
Höpital Avicenne University (France)

8:50 a.m. Session I: Scientific and Clinical Challenges

  Overview and Scientific Challenges and Questions
Cheryl L. Willman, M.D
University of New Mexico Cancer Research and Treatment Center

Prognostic and Predictive Markers of Tomorrow
Eva Hellstrom-Lindberg, M.D., Ph.D.
Karolinska Institutet (Sweden)

Clinical Challenges and Questions
Guillermo Garcia-Manero, M.D.
MD Anderson Cancer Center

  Roundtable Discussion


11:00 a.m. Session II: Biology and Pathophysiology

Benjamin L. Ebert, M.D., Ph.D.
Brigham and Women's Hospital

Microenvironment in the Regulation of Normal and MDS Stem Cells
David T. Scadden, M.D.
Massachusetts General Hospital / Harvard Stem Cell Institute

Genetic Lesions that Phenocopy Dysplasia and Progression to AML
Peter D. Aplan, M.D.
National Cancer Institute

Bone Marrow Failure Syndromes and MDS
Monica Bessler, M.D., Ph.D.
University of Pennsylvania

Roundtable Discussion

12:45 p.m. Lunch

1:30 p.m. Session III: MDS Genomics

Timothy Graubert, M.D.
Washington University in St. Louis

Inherited Predisposition to MDS: Syndromic, Familial, and
   Sporadic Mutations

Marshall S. Horwitz, M.D., Ph.D.
University of Washington

Mutation Discovery in MDS Using Next-generation Sequencing
Mathew J. Walter, M.D.
Washington University in St. Louis

Biological Consequences of Mutations in the 5q Commonly Deleted Interval
Benjamin L. Ebert, M.D., Ph.D.
Brigham and Women's Hospital

Roundtable Discussion


3:35 p.m. Session IV: MDS Epigenomics

Jaroslaw P. Maciejewski, M.D., Ph.D.
Cleveland Clinic

MDS Methylome and Array-based Screens
Ari M. Melnick, M.D.
Weill Cornell Medical College

Genetic Drivers of Aberrant DNA Methylation and Demethylation in MDS
Jaroslaw P. Maciejewski, M.D., Ph.D.
Cleveland Clinic

Characterization of Abnormal Histone Modification and Genetic
    Drivers in MDS

James G. Herman, M.D.
John Hopkins University

Roundtable Discussion

6:00 p.m. Adjourn

Thursday, September 8, 2011

8:00 - 9:30 a.m. Session V: Improved Therapeutic Outcomes

Eva Hellstrom-Lindberg, M.D., Ph.D.
Karolinska Institutet (Sweden)

MDS Stem Cells and Therapies: Enhancing Cure Rate-biomarkers for
    Resistant Disease and Risk of Relapse

Sten Erik W. Jacobsen, M.D., Ph.D.
University of Oxford (UNITED KINGDOM)

High Risk Disease and Relapse: Prospects of Epigenetic Therapy
Steven D. Gore, M.D.
Johns Hopkins University

Low-risk MDS and Anemia: Biomarkers for Selecting Optimal Treatment
   for Cytopenia

Stephen D. Nimer, M.D.
Memorial Sloan-Kettering Cancer Center

Roundtable Discussion

  Session VI: Summary and Discussion

Pierre Fenaux, M.D., Ph.D.
Hôpital Avicenne University (France)

Hal E. Broxmeyer, Ph.D.
Indiana School of Medicine

Noon Adjournment

Last Updated January 2012

Skip footer links and go to content
Twitter iconTwitterExternal link Disclaimer         Facebook iconFacebookimage of external link icon         YouTube iconYouTubeimage of external link icon         Google+ iconGoogle+image of external link icon